QuidelOrtho Corporation Common Stock (QDEL)
QuidelOrtho Corporation (QDEL) is a global leader in the development and manufacturing of diagnostic healthcare products. The company specializes in rapid diagnostic testing solutions, including point-of-care tests for infectious diseases, cardiac health, and respiratory illnesses. Formed from the merger of Quidel Corporation and Ortho Clinical Diagnostics, QuidelOrtho offers a broad portfolio of products used in hospitals, laboratories, and clinics to facilitate timely and accurate disease detection and management.
Company News
Law firm investigating potential claims against QuidelOrtho for allegedly misleading investors about COVID-19 test revenues and product launch during 2022-2024, with significant earnings miss and revenue forecast reduction in February 2024.
QuidelOrtho reported Q2 FY2025 financial results with narrowly surpassed revenue estimates, improved adjusted EPS, and significant restructuring charges, reflecting ongoing market contraction and strategic shifts in diagnostic testing solutions.
The global infectious disease diagnostics market is projected to reach $43.09 billion by 2031, growing at a CAGR of 8.20% during the forecast period. The market is driven by advancements in diagnostic technologies, rising cases of infectious diseases, and increased R&D funding.
Entities associated with the Carlyle Group have sold over $4.8 million worth of shares in QuidelOrtho Corp, a company specializing in diagnostic substances. The sales were conducted in accordance with a Rule 10b5-1 trading plan, and the entities still hold a significant number of shares in the company.
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.